Synpromics, UCL to develop gene therapy for PD

Synpromics Ltd. (Edinburgh, U.K.) partnered with University College London to generate synthetic CNS gene promoters and develop a gene therapy for Parkinson's disease.

Synpromics Founder and CSO Michael Roberts told BioCentury that the company will use its PromPt platform to design and build candidate promoters for multiple neuronal cell types, and that UCL will then insert those promoters into AAV gene vectors and assess their activity in different neuronal populations. Both partners will then select optimal gene switches for UCL to develop gene therapy vectors to treat young-onset PD...